JP5954877B2 - 負荷率の改善が可能な抗癌剤送達ビヒクル - Google Patents

負荷率の改善が可能な抗癌剤送達ビヒクル Download PDF

Info

Publication number
JP5954877B2
JP5954877B2 JP2012557010A JP2012557010A JP5954877B2 JP 5954877 B2 JP5954877 B2 JP 5954877B2 JP 2012557010 A JP2012557010 A JP 2012557010A JP 2012557010 A JP2012557010 A JP 2012557010A JP 5954877 B2 JP5954877 B2 JP 5954877B2
Authority
JP
Japan
Prior art keywords
flavonoid
peg
egcg
conjugate
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2012557010A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013522189A5 (enExample
JP2013522189A (ja
Inventor
元一 栗沢
元一 栗沢
クン リャン，
クン リャン，
スシ タン，
スシ タン，
ジュ ウ チャン，
ジュ ウ チャン，
ジャッキー ワイ． イン，
ジャッキー ワイ． イン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Agency for Science, Technology and Research
Original Assignee
Agency for Science, Technology and Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agency for Science, Technology and Research filed Critical Agency for Science, Technology and Research
Publication of JP2013522189A publication Critical patent/JP2013522189A/ja
Publication of JP2013522189A5 publication Critical patent/JP2013522189A5/ja
Application granted granted Critical
Publication of JP5954877B2 publication Critical patent/JP5954877B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2012557010A 2010-03-11 2011-03-11 負荷率の改善が可能な抗癌剤送達ビヒクル Expired - Fee Related JP5954877B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31288510P 2010-03-11 2010-03-11
US61/312,885 2010-03-11
PCT/SG2011/000100 WO2011112156A1 (en) 2010-03-11 2011-03-11 Anti-cancer agent delivery vehicles capable of improved laoding

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016053960A Division JP2016153415A (ja) 2010-03-11 2016-03-17 負荷率の改善が可能な抗癌剤送達ビヒクル

Publications (3)

Publication Number Publication Date
JP2013522189A JP2013522189A (ja) 2013-06-13
JP2013522189A5 JP2013522189A5 (enExample) 2014-04-24
JP5954877B2 true JP5954877B2 (ja) 2016-07-20

Family

ID=44563737

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012557010A Expired - Fee Related JP5954877B2 (ja) 2010-03-11 2011-03-11 負荷率の改善が可能な抗癌剤送達ビヒクル
JP2016053960A Pending JP2016153415A (ja) 2010-03-11 2016-03-17 負荷率の改善が可能な抗癌剤送達ビヒクル

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2016053960A Pending JP2016153415A (ja) 2010-03-11 2016-03-17 負荷率の改善が可能な抗癌剤送達ビヒクル

Country Status (5)

Country Link
US (2) US9687464B2 (enExample)
EP (1) EP2544768A4 (enExample)
JP (2) JP5954877B2 (enExample)
SG (2) SG10201501829YA (enExample)
WO (1) WO2011112156A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101909655B (zh) * 2007-10-23 2013-04-10 新加坡科技研究局 递送抗癌剂至细胞的方法
EP2435504B1 (en) 2009-05-29 2020-03-11 Agency For Science, Technology And Research Flavonoid hydrogel
US8933078B2 (en) 2011-07-14 2015-01-13 Research Cancer Institute Of America Method of treating cancer with combinations of histone deacetylase inhibitors (HDAC1) substances
CN105658633A (zh) 2013-09-03 2016-06-08 新加坡科技研究局 用于生物医药应用的聚合物-类黄酮缀合物和水凝胶
CU24520B1 (es) * 2014-05-09 2021-06-08 Agency Science Tech & Res Nanocomplejo micelar de conjugados de polímero-flavonoide para la administración de fármacos antitumorales
WO2015183970A1 (en) * 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including flavonoid and uses thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
WO2018124970A1 (en) * 2016-12-30 2018-07-05 Agency For Science, Technology And Research A nanocomplex
WO2018157081A1 (en) 2017-02-27 2018-08-30 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2018170457A1 (en) 2017-03-17 2018-09-20 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
WO2019099750A1 (en) 2017-11-17 2019-05-23 Research Cancer Institute Of America Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
CN111973754A (zh) * 2019-05-21 2020-11-24 杭州磐田生物技术有限公司 含药物纳米颗粒及其制备方法和应用
EP4522128A4 (en) * 2022-05-13 2026-05-13 Suntec Medical Inc Method for treating infectious disease
JP2025517354A (ja) * 2022-05-16 2025-06-05 サンテック メディカル，インコーポレイティド 自己免疫疾患を治療する方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586612B2 (en) * 2001-11-16 2003-07-01 Crompton Corporation Process for the preparation of secondary and tertiary amino-functional silanes, iminoorganosilanes and/or imidoorganosilanes
US7858080B2 (en) * 2005-05-20 2010-12-28 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
AU2006248166B2 (en) * 2005-05-20 2012-11-01 Agency For Science, Technology And Research Aldehyde conjugated flavonoid preparations
WO2008105773A2 (en) * 2006-03-31 2008-09-04 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
CN101909655B (zh) 2007-10-23 2013-04-10 新加坡科技研究局 递送抗癌剂至细胞的方法
EP2435504B1 (en) 2009-05-29 2020-03-11 Agency For Science, Technology And Research Flavonoid hydrogel
SG178369A1 (en) 2009-08-11 2012-04-27 Agency Science Tech & Res Particulate hyaluronic acid formulations for cellular delivery of bioactive agents

Also Published As

Publication number Publication date
US20130004488A1 (en) 2013-01-03
EP2544768A4 (en) 2016-02-24
SG10201501829YA (en) 2015-05-28
EP2544768A1 (en) 2013-01-16
US9687464B2 (en) 2017-06-27
SG184027A1 (en) 2012-10-30
JP2013522189A (ja) 2013-06-13
JP2016153415A (ja) 2016-08-25
US20170258757A1 (en) 2017-09-14
WO2011112156A1 (en) 2011-09-15

Similar Documents

Publication Publication Date Title
JP2016153415A (ja) 負荷率の改善が可能な抗癌剤送達ビヒクル
Luong et al. Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers
Feldmann et al. In vitro and in vivo delivery of siRNA via VIPER polymer system to lung cells
JP5937966B2 (ja) 生体活性物質の細胞送達のための粒子状ヒアルロン酸製剤
Li et al. Dual redox/pH-responsive hybrid polymer-lipid composites: Synthesis, preparation, characterization and application in drug delivery with enhanced therapeutic efficacy
Navarro et al. Phospholipid–polyethylenimine conjugate-based micelle-like nanoparticles for siRNA delivery
Lee et al. PEGylated DC-Chol/DOPE cationic liposomes containing KSP siRNA as a systemic siRNA delivery Carrier for ovarian cancer therapy
Li et al. Amphiphilic dendrimer engineered nanocarrier systems for co-delivery of siRNA and paclitaxel to matrix metalloproteinase-rich tumors for synergistic therapy
Chen et al. A pH-responsive cyclodextrin-based hybrid nanosystem as a nonviral vector for gene delivery
Patil et al. Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery
Xu et al. Folic acid-decorated polyamidoamine dendrimer exhibits high tumor uptake and sustained highly localized retention in solid tumors: Its utility for local siRNA delivery
Essex et al. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors
Lee et al. Self-assembled siRNA–PLGA conjugate micelles for gene silencing
CN101909655B (zh) 递送抗癌剂至细胞的方法
Gu et al. Reversal of P-glycoprotein-mediated multidrug resistance by CD44 antibody-targeted nanocomplexes for short hairpin RNA-encoding plasmid DNA delivery
Sarisozen et al. Polymers in the co-delivery of siRNA and anticancer drugs to treat multidrug-resistant tumors
David-Naim et al. Polymeric nanoparticles of siRNA prepared by a double-emulsion solvent-diffusion technique: Physicochemical properties, toxicity, biodistribution and efficacy in a mammary carcinoma mice model
Yang et al. Charge-reversal-functionalized PLGA nanobubbles as theranostic agents for ultrasonic-imaging-guided combination therapy
WO2010042823A1 (en) Multifunctional self-assembling polymeric nanosystems
WO2012024396A2 (en) Compositions and methods for delivering nucleic acid molecules and treating cancer
WO2019110067A1 (en) Hybrid nanoparticle
US20250099497A1 (en) Conjugation of lipophilic albumin-binding moiety to rna for improved carrier-free in vivo pharmacokinetics and gene silencing
WO2011011631A2 (en) Nucleic acid delivery vehicles
Yang Development of novel gene delivery system for cancer therapy
Yin RNA nanoparticles for anti-oncogenic miRNA and drug delivery for cancer therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140310

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20141219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150406

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20150507

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160317

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160325

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160517

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160610

R150 Certificate of patent or registration of utility model

Ref document number: 5954877

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees